Protalix BioTherapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
PLX$2.54+1.2%Stored close · as of Nov 6, 2026
Contents
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | |
|---|---|---|
| | | PROTALIX BIOTHERAPEUTICS, INC. |
| | | (Registrant) |
| | | |
| Date: May 13, 2026 | By: | /s/ Dror Bashan |
| | | Dror BashanPresident and Chief Executive Officer(Principal Executive Officer) |
| | | |
| Date: May 13, 2026 | By: | /s/ Gilad Mamlok |
| | | Gilad MamlokSenior Vice President and Chief Financial Officer, Treasurer and Secretary(Principal Financial and Accounting Officer) |
| | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.